20/20 BioLabs Announces Standstill Agreement with Streeterville Capital Regarding Series E Convertible Preferred Stock

20/20 BioLabs (Nasdaq: AIDX) entered a standstill agreement with Streeterville Capital effective July 16, 2026, covering its outstanding Series E Convertible Preferred Stock.

Rhea-AI Summary

20/20 BioLabs (Nasdaq: AIDX) entered a standstill agreement with Streeterville Capital effective July 16, 2026, covering its outstanding Series E Convertible Preferred Stock. For 120 days, Streeterville will not convert preferred shares to common stock unless AIDX trades at least 10% above the Nasdaq “Minimum Price.”

The arrangement is designed to temporarily limit potential dilution from preferred conversions while keeping all existing rights and obligations under the Series E Preferred Stock and related transaction documents otherwise unchanged. After the standstill ends or is terminated, conversions may resume under existing terms.

Positive

• 120-day cap on conversions below 10% above Nasdaq Minimum Price
• Standstill may reduce near-term dilution from Series E conversions
• Existing Series E and related documents remain in full force

Negative

• Standstill is temporary, lasting only 120 days from July 16, 2026
• Standstill ends immediately upon any breach or Event of Default
• Streeterville can fully resume conversions after standstill expiration

Argus Jul 23 session 11 alerts

-6.76% close to close 0.7x rel. volume Open Argus

Details

Market reaction after Series E standstill agreement: AIDX -6.76% in the Jul 23 session

-12.4% Trough in 13 hr 37 min

$6.73M Market Cap

In the Jul 23 session, AIDX declined 6.76%, reflecting a notable negative market reaction. Argus tracked a trough of -12.4% from its starting point during tracking. Our momentum scanner triggered 11 alerts that day, indicating notable trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The stock moved -6.8% in the session following this news. AIDX’s May 27 screening announcement was f...

Analysis

The stock moved -6.8% in the session following this news. AIDX’s May 27 screening announcement was followed by a -4.9% 24-hour move, showing that favorable operational news previously diverged from trading response. Here, the standstill limits near-term conversions, while conversion rights remain after termination.

Key Figures

Announcement Date: July 23, 2026 Agreement Effective Date: July 16, 2026 Standstill Period: 120 days +1 more

Announcement Date

July 23, 2026

Article dateline

Agreement Effective Date

July 16, 2026

Standstill agreement

Standstill Period

120 days

Beginning on the agreement date

Conversion Price Threshold

10% above the Minimum Price

Condition for preferred-to-common conversions during the standstill

Historical Context

5 past events · Latest: Jul 09

5 events

1. Jul 09

   Investor webinar

   24h Move

   +1.1%

   Focused on OneTest, Medicare strategy, and preliminary Q2 revenue growth expectations

2. Jun 22

   Webinar series launch

   24h Move

   +2.8%

   Announced recurring investor webinars and an inaugural July 1 session with management access

3. May 27

   Screening program selection

   24h Move

   -4.9%

   Selected for Vermont firefighter screening program expected to generate about $500,000

4. May 22

   Testing contingency planning

   24h Move

   -18.7%

   Prepared potential Ebola and Hantavirus PCR testing capacity without current authorization

5. May 20

   First-quarter earnings

   24h Move

   -6.6%

   Reported lower revenue, wider net loss, and improved liquidity after financing

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

standstill agreement, convertible preferred stock, event of default

3 terms

standstill agreement financial

"today announced that it has entered into a standstill agreement"

A standstill agreement is a contract in which one party agrees to pause certain actions — such as making new claims, enforcing debt remedies, or pursuing a takeover bid — for a set period so both sides can negotiate or restructure. Think of it as a temporary pause button that reduces immediate pressure and uncertainty; investors care because it can protect value, buy time for a deal or restructuring to be completed, and signal the likelihood and timing of future corporate developments.

convertible preferred stock financial

"outstanding Series E Convertible Preferred Stock"

Convertible preferred stock is a special class of company shares that pays priority, usually fixed, payments to holders and can be exchanged later for a set number of common shares. It matters to investors because it combines steady income and added protection with the chance to share in a company’s upside; think of it as a hybrid between a bond that pays regularly and an option to convert into growth-oriented stock, where the conversion rules influence both potential gains and how much common shareholders’ ownership may be reduced.

event of default regulatory

"any Event of Default as defined in the Certificate of Designation"

An event of default is a specific breach of a loan or bond agreement—such as missed payments or breaking agreed rules—that gives lenders the legal right to act, for example by demanding immediate repayment, seizing collateral, or accelerating other obligations. For investors, it’s a red flag because it can sharply reduce a company’s ability to operate or raise money, like a car lender repossessing a vehicle after missed payments, and often leads to falling share or bond prices.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Agreement Temporarily Restricts Preferred-to-Common Stock Conversions Below a Defined Price Threshold, Mitigating Potential Near-Term Dilution

GAITHERSBURG, Md., July 23, 2026 (GLOBE NEWSWIRE) -- 20/20 BioLabs, Inc. (Nasdaq: AIDX) (the “Company”), an early market entrant in AI-powered, laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases, today announced that it has entered into a standstill agreement (the “Agreement”) with Streeterville Capital, LLC (“Streeterville”) relating to the Company’s outstanding Series E Convertible Preferred Stock (the “Series E Preferred Stock”). The Agreement became effective on July 16, 2026.

Under the terms of the Agreement, during the 120-day period beginning on the date of the Agreement, Streeterville has agreed not to convert any shares of Series E Preferred Stock into shares of the Company’s common stock unless, on a given trading day, the common stock trades at a price at least 10% above the “Minimum Price” (as defined under Nasdaq Rule 5635) (the “Standstill”) provided that the Standstill shall terminate immediately upon the occurrence of any breach of the Agreement or any Event of Default (as defined in the Certificate of Designation for the Series E Preferred Stock). The Agreement temporarily limits potential dilution from conversions of the Series E Preferred Stock while preserving the existing rights and obligations of both parties under the related transaction documents.

Upon expiration or termination of the Standstill, Streeterville may resume converting shares of the Series E Preferred Stock in accordance with the terms of the applicable transaction documents. Except as expressly provided in the Agreement, the Series E Preferred Stock and all related transaction documents remain in full force and effect.

Additional information regarding the Agreement will be included in a Current Report on Form 8-K to be filed with the U.S. Securities and Exchange Commission.

About 20/20 BioLabs

20/20 BioLabs, Inc. (Nasdaq: AIDX) develops and commercializes AI-powered, laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases. The Company offers two families of lab tests under the OneTest brand. OneTest™ for Cancer is a multi-cancer early detection, or MCED, blood test, and OneTest™ for Longevity measures inflammatory biomarkers and is commercially available. OneTest’s affordable, accurate, accessible tests can be conveniently utilized at home using new, upper-arm capillary collection devices that avoid painful needles. Tests are run in the Company’s College of American Pathologists (CAP) accredited, Clinical Laboratory Improvement Amendments (CLIA) licensed laboratory in Gaithersburg, Maryland.

For more information visit https://2020biolabs.com.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements regarding the expected effects of the Agreement, including its anticipated impact on conversion activity, dilution and the trading market for the Company’s common stock, as well as the Company’s business strategy and prospects. These statements are often identified by words such as “believe,” “expect,” “intend,” “anticipate,” “plan,” “may,” “will,” “should” and similar expressions. Forward-looking statements are based on management’s current expectations and assumptions and are subject to known and unknown risks and uncertainties that could cause actual results to differ materially from those expressed or implied. There can be no assurance that the Agreement will have the intended effects, that the standstill will not terminate early, or that Streeterville will not convert shares of Series E Preferred Stock following the standstill period. Additional factors are described in the Company’s filings with the U.S. Securities and Exchange Commission, including its Annual Report on Form 10-K and subsequent reports. The Company undertakes no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Investor Relations
Chris Tyson
MZ Group
Direct: 949-491-8235
AIDX@mzgroup.us

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did 20/20 BioLabs (AIDX) announce about its Series E Convertible Preferred Stock on July 23, 2026?

20/20 BioLabs announced a 120-day standstill agreement with Streeterville Capital limiting conversions of Series E Preferred into common stock. According to the company, conversions are restricted unless the share price is at least 10% above the Nasdaq-defined Minimum Price.

How does the 20/20 BioLabs (AIDX) standstill agreement with Streeterville Capital affect share dilution?

The standstill is intended to temporarily limit potential dilution from converting Series E Preferred into common shares. According to 20/20 BioLabs, Streeterville may only convert during the 120-day period when AIDX common stock trades at least 10% above the Nasdaq Minimum Price.

What is the duration of the 20/20 BioLabs (AIDX) standstill agreement on Series E Preferred conversions?

The standstill agreement lasts for 120 days starting July 16, 2026. During this period, according to 20/20 BioLabs, Streeterville cannot convert Series E Preferred into common stock unless the trading price is at least 10% above the Nasdaq-defined Minimum Price.

Under what conditions can Streeterville Capital convert 20/20 BioLabs (AIDX) Series E Preferred Stock during the standstill?

Streeterville can convert Series E Preferred only on days AIDX common stock trades at least 10% above the Nasdaq Minimum Price. According to 20/20 BioLabs, this restriction applies throughout the 120-day standstill, absent breach or an Event of Default.

What happens to 20/20 BioLabs (AIDX) Series E Preferred Stock terms after the standstill ends?

After expiration or termination of the standstill, Streeterville may resume converting Series E Preferred under existing transaction terms. According to 20/20 BioLabs, all Series E and related documents otherwise remain in full force and effect during and after the standstill.

Does the 20/20 BioLabs (AIDX) standstill agreement change existing rights under the Series E Preferred Stock?

The agreement does not change existing rights or obligations apart from the temporary conversion restriction. According to 20/20 BioLabs, the Series E Preferred Stock and all related transaction documents remain in full force and effect, except as expressly modified by the standstill.